公开(公告)号：US12011481B2

公开(公告)日：2024-06-18

申请号：US17147252

申请日：2021-01-12

申请人： Agenus Inc.

发明人： Marc van Dijk ,  Ekaterina Vladimirovna Breous-Nystrom ,  Nicholas Stuart Wilson ,  Jeremy Dale Waight ,  Dennis John Underwood

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： A61K39/395 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/55

摘要： The instant disclosure provides antibodies that specifically bind to TIM 3 and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

公开(公告)号：US20240100156A1

公开(公告)日：2024-03-28

申请号：US18166938

申请日：2023-02-09

申请人： NeoTX Therapeutics Ltd.

发明人： Asher Nathan ,  Michal Shahar

IPC分类号： A61K39/395 ,  A61K38/16 ,  A61K39/00 ,  A61K39/085 ,  A61K47/68 ,  C07K14/31 ,  C07K16/28 ,  C07K16/30

CPC分类号： A61K39/39558 ,  A61K38/164 ,  A61K39/0011 ,  A61K39/085 ,  A61K39/39541 ,  A61K39/3955 ,  A61K47/6829 ,  A61K47/6851 ,  C07K14/31 ,  C07K16/2818 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3053 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/585 ,  A61K2039/6056 ,  A61K2039/86 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/40 ,  C07K2319/55 ,  C07K2319/74

摘要： The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.

公开(公告)号：US20230416309A1

公开(公告)日：2023-12-28

申请号：US18249904

申请日：2021-10-22

申请人： JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION (PUBLIC HEALTH RESEARCH INSTITUTE OF JI ,  JIANGSU RECBIO TECHNOLOGY CO., LTD. ,  BEIJING ABZYMO BIOSCIENCES CO., LTD.

发明人： Fengcai ZHU ,  Jiaping YU ,  Wenrong YAO ,  Chuxiao YUAN ,  Shuang WU ,  Yanyan ZHANG ,  Yingsong HU ,  Xiling GUO ,  Ling ZHANG ,  Li XIA ,  Li ZHANG ,  Jingxin LI ,  Hongxing PAN ,  Jianping CHEN ,  Yong LIU

IPC分类号： C07K14/005 ,  A61K39/215 ,  A61P31/14

CPC分类号： C07K14/005 ,  A61K39/215 ,  A61P31/14 ,  C12N2770/20022 ,  C12N2770/20034 ,  C07K2319/40 ,  C07K2319/00 ,  C07K2319/55 ,  C07K2319/42

摘要： The present application relates to one or more fusion proteins, comprising a structural domain of SARS-CoV-2 S(Spike) protein. The present application also relates to an immunogenic composition comprising the fusion protein and an application thereof.

公开(公告)号：US11795235B2

公开(公告)日：2023-10-24

申请号：US16648369

申请日：2018-09-18

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： Ira H. Pastan ,  Junxia Wei ,  Masanori Onda ,  Tapan Bera ,  Mitchell Ho

IPC分类号： C07K14/21 ,  C07K16/28 ,  C07K16/30

CPC分类号： C07K16/30 ,  C07K14/21 ,  C07K16/2803 ,  C07K16/2866 ,  C07K16/2878 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/624 ,  C07K2317/73 ,  C07K2317/94 ,  C07K2319/33 ,  C07K2319/50 ,  C07K2319/55 ,  C07K2319/70

摘要： Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.

公开(公告)号：US20230331788A1

公开(公告)日：2023-10-19

申请号：US18325199

申请日：2023-05-30

申请人： NATIONAL RESEARCH COUNCIL OF CANADA

发明人： Luke MASSON ,  Melanie ARBOUR ,  Marie-Anne GAURIAT

IPC分类号： C07K14/34 ,  C07K1/22 ,  C12N15/70 ,  C12N15/90

CPC分类号： C07K14/34 ,  C07K1/22 ,  C12N15/70 ,  C12N15/902 ,  C07K2319/034 ,  C07K2319/55 ,  C12N2500/24 ,  C12N2500/34 ,  C12N2500/35 ,  C12N2500/74

摘要： An expression system and process for the production of Diphtheria toxin polypeptides or mutated forms thereof, such as the toxoid CRM197 polypeptide, in genetically-modified E. coli with high yield is described. The system and process is based on the uncoupling of biomass growth from recombinant protein induction, i.e. using an inducer of protein production that cannot be used as a carbon source for growth by the bacteria. The use of specific components and conditions that improve protein yields are also described.

公开(公告)号：US20230312679A1

公开(公告)日：2023-10-05

申请号：US18154091

申请日：2023-01-13

申请人： Immatics Biotechnologies GmbH

发明人： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC分类号： C07K14/74 ,  A61K51/10 ,  C12N15/115 ,  G01N33/569 ,  C12P21/02 ,  C07K14/47 ,  C12Q1/6881 ,  C07K14/705 ,  C12N5/0783 ,  A61K39/00 ,  C07K16/28 ,  C07K16/30

CPC分类号： C07K14/70539 ,  A61K39/0011 ,  A61K51/1027 ,  A61K51/1057 ,  C07K14/4748 ,  C07K14/70503 ,  C07K16/303 ,  C07K16/2833 ,  C12N5/0636 ,  C12N15/115 ,  C12P21/02 ,  C12Q1/6881 ,  G01N33/56977 ,  A61K2039/572 ,  A61K2039/5158 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/55 ,  C12N2310/16 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2333/70539

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11753466B2

公开(公告)日：2023-09-12

申请号：US16723809

申请日：2019-12-20

申请人： CytomX Therapeutics, Inc.

发明人： James William West ,  Jason Gary Sagert ,  Jonathan Alexander Terrett ,  Annie Yang Weaver ,  Luc Roland Desnoyers ,  Shweta Singh

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61K31/537 ,  A61K39/00

CPC分类号： C07K16/2803 ,  A61K31/537 ,  A61K47/6873 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/50 ,  C07K2319/55

摘要： The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

公开(公告)号：US20230257427A1

公开(公告)日：2023-08-17

申请号：US17930683

申请日：2022-09-08

申请人： Vestaron Corporation

发明人： Robert M. KENNEDY ,  William Tedford ,  Christopher Hendrickson ,  Robert Venable ,  Catherine L. Foune ,  John Mcintyre ,  Alvar R. Carlson ,  Lin Bao

IPC分类号： C07K14/435 ,  C12N15/82 ,  A01N63/50

CPC分类号： C07K14/43518 ,  C07K14/43504 ,  C12N15/8286 ,  A01N63/50 ,  C07K2319/55 ,  Y02A40/146

摘要： New insecticidal proteins, nucleotides, peptides, their expression in plants, methods of producing the peptides, new processes, production techniques, new peptides, new formulations, and new organisms, a process which increases the insecticidal peptide production yield from yeast expression systems. The present invention is also related and discloses selected endotoxins we call cysteine rich insecticidal peptides (CRIPS) which are peptides derived from Bacillus thuringiensis (Bt) and their genes and endotoxins in combination with toxic peptides known as Inhibitor Cystine Knot (ICK) genes and peptides as well as with other types of insecticidal peptides such as trypsin modulating oostatic factor (TMOF) peptide sequences used in various formulations and combinations; of both genes and peptides, useful for the control of insects.

公开(公告)号：US20230220045A1

公开(公告)日：2023-07-13

申请号：US18154098

申请日：2023-01-13

申请人： Immatics Biotechnologies GmbH

发明人： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC分类号： C07K14/74 ,  C07K16/30 ,  C07K16/28 ,  C12P21/02 ,  A61K51/10 ,  A61K39/00 ,  C12Q1/6881 ,  C07K14/47 ,  C12N15/115 ,  C12N5/0783 ,  G01N33/569 ,  C07K14/705

CPC分类号： C07K14/70539 ,  C07K16/303 ,  C07K16/2833 ,  C12P21/02 ,  A61K51/1027 ,  A61K51/1057 ,  A61K39/0011 ,  C12Q1/6881 ,  C07K14/4748 ,  C12N15/115 ,  C12N5/0636 ,  G01N33/56977 ,  C07K14/70503 ,  A61K2039/5158 ,  G01N2333/70539 ,  C12Q2600/156 ,  C12N2310/16 ,  C12Q2600/158 ,  C07K2319/55 ,  C07K2319/30 ,  C07K2319/00 ,  C07K2317/72 ,  C07K2317/73 ,  A61K2039/572

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11684661B2

公开(公告)日：2023-06-27

申请号：US16858924

申请日：2020-04-27

申请人： THE JOHNS HOPKINS UNIVERSITY ,  SOUTH DAKOTA STATE UNIVERSITY

发明人： David A. Sack ,  Weiping Zhang

IPC分类号： A61K39/108 ,  C07K14/245 ,  A61K39/08 ,  A61K45/06 ,  A61K39/00

CPC分类号： A61K39/0258 ,  A61K39/08 ,  A61K45/06 ,  C07K14/245 ,  A61K2039/575 ,  A61K2039/6037 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/55

摘要： Provided herein are polypeptides comprising up to 9 antigenic elements of ETEC virulence determinants: 7 CFA adhesins [CFA/I, CFA/II (CS1, CS2, CS3), CFA/IV (CS4, CS5, CS6)] expressed by the most prevalent and virulent ETEC strains, and 2 toxins expressed by all ETEC strains, were genetically fused together for CFA-toxoid fusion with proteins (CFA/I/II/IV-STatoxoid-LTtoxoid). Methods for making these polypeptides and their use in the treatment of ETEC related disease are also provided.